Bradley Pharmaceuticals creates A. Aarons subsidiary to market generic drugs

By Angela McDaniels

Seattle, Jan. 4 - Bradley Pharmaceuticals Inc. said it has established a subsidiary, A. Aarons Inc., to market generic therapies provided by Bradley's Doak Dermatologics and Kenwood Therapeutics operating units.

The new subsidiary was created to mitigate revenue lost to generic competition.

A. Aarons will be headed by William Renzo, vice president of trade and managed care relations for Bradley Pharmaceuticals, and will likely begin operations during the first quarter of 2006.

"The Bradley management team believes that the establishment of A. Aarons as a Bradley subsidiary reflects the company's ongoing commitment to life cycle management," Bradley president and chief executive officer Daniel Glassman said in a company news release.

Bradley is a specialty pharmaceutical company based in Fairfield, N.J., with a focus on acquiring, improving and promoting branded pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.